50715-28-1

Basic information

• Product Name: Cyclopentyl chloroformate
• Synonyms: CYCLOPENTYL CHLOROFORMATE;CARBONOCHLORIDIC ACID, CYCLOPENTYL ESTER;Cyclopentyl carbonochloridoate;Cyclopentyl carbonochloridate;Cyclopentyl carbonochloridoate, [(Chlorocarbonyl)oxy]cyclopentane, [(Chloroformyl)oxy]cyclopentane
• CAS NO: 50715-28-1
• Molecular Formula: C₆H₉ClO₂
• Molecular Weight: 148.59
• EINECS: 411-460-0
• Product Categories: CHLOROFORMATES;Ring Systems
• Mol File: 50715-28-1.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 173.32 °C at 760 mmHg
• Flash Point: 66.742 °C
• Appearance: /
• Density: 1.19 g/cm³
• Vapor Pressure: 1.27mmHg at 25°C
• Refractive Index: 1.463
• CAS DataBase Reference: Cyclopentyl chloroformate(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopentyl chloroformate(50715-28-1)
• EPA Substance Registry System: Cyclopentyl chloroformate(50715-28-1)

Safety Data

• Hazard Codes: Xi,T
• Statements: 10-22-23-41-43-48/22
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 50715-28-1(Hazardous Substances Data)

Usage

Description

Cyclopentyl chloroformate is an organic compound that serves as a valuable chemical reagent in the synthesis of various pharmaceutical compounds. It is characterized by its ability to form stable carbamates, making it a versatile building block in the development of new drugs and bioactive molecules.

Uses

Used in Pharmaceutical Industry:
Cyclopentyl chloroformate is used as a key intermediate in the synthesis of novel peptidomimetic Hepatitis C (Hep C) protease inhibitors. These inhibitors are designed to target and inhibit the activity of the Hep C virus protease enzyme, which is essential for the virus's replication process. By incorporating cyclopentyl chloroformate into the molecular structure of these inhibitors, researchers can develop more potent and selective antiviral agents to combat Hepatitis C.
Additionally, due to its reactivity in forming carbamates, cyclopentyl chloroformate may also be utilized in the development of other bioactive compounds and pharmaceuticals, further expanding its applications in the pharmaceutical industry.

InChI:InChI=1/C6H9ClO2/c7-6(8)9-5-3-1-2-4-5/h5H,1-4H2

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 96-41-3 Cyclopentanol 
• 503-38-8 trichloromethyl chloroformate 
• 1003-03-8 Cyclopentamine 
• 75-44-5 phosgene 

Downstream Products

• 141037-00-5 Carbonic acid cyclohex-2-enyl ester cyclopentyl ester 
• 141036-97-7 Carbonic acid cyclopentyl ester 1-phenyl-ethyl ester 
• 141451-91-4 methyl 1-[3-(cyclopentyloxycarbonylamino)benzyl]-indole-5-carboxylate 
• 572924-00-6 N-[(cyclopentyloxy)carbonyl]-L-tert-leucine 

Relevant articles and documents

Versatile Cp*Co(III)(LX) Catalyst System for Selective Intramolecular C-H Amidation Reactions

Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed regioselectivity was rationalized by the conformational analysis and DFT calculations of the transition states. The superior performance of the newly developed cobalt catalyst system could be broadly applied to both C(sp2)-H and C(sp3)-H carbamation reactions under mild conditions.

PYRROLIDINE DERIVATIVES AS PPAR AGONISTS

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells

Elevated reactive oxygen species and antioxidant defense systems have been recognized as one of the hallmarks of cancer cells. As a major regulator of the cellular redox homeostasis, the selenoprotein thioredoxin reductase (TrxR) is increasingly considered as a promising target for anticancer drug development. The current approach to inhibit TrxR predominantly relies on the modification of the selenocysteine residue in the C-terminal active site of the enzyme, in which it is hard to avoid the off-target effects. By conjugating the anticancer drug gemcitabine with a 1,2-dithiolane scaffold, an unprecedented prodrug strategy is disclosed that achieves a specific release of gemcitabine by TrxR in cells. As overexpression of TrxR is frequently found in different types of tumors, the TrxR-dependent prodrugs are promising for further development as cancer chemotherapeutic agents.